Metabolic Surgery Rates Drop as GLP-1 Uptake Increases

Metabolic Surgery Rates Drop as GLP-1 Uptake Increases

The treatment landscape for obesity and metabolic disorders is undergoing a notable shift. Over the past few years, prescriptions for glucagon-like peptide-1 (GLP-1) receptor agonists have surged, while the number of metabolic surgeries performed in hospitals has declined. These two trends appear to move in opposite directions, raising questions about how patients and providers are rethinking long-term weight management strategies. While the data is still evolving, the pattern suggests that pharmacological options are increasingly competing with surgical interventions for the first time in decades.

GLP-1 Uptake on the Rise

GLP-1 receptor agonists, originally developed for type 2 diabetes, have gained substantial traction as weight loss therapies. The class includes medications such as semaglutide (marketed under names like Ozempic and Wegovy), liraglutide (Saxenda), and tirzepatide (Mounjaro and Zepbound). These drugs mimic the natural incretin hormone GLP-1, which stimulates insulin secretion, slows gastric emptying, and promotes satiety by acting on hypothalamic receptors. Clinical trials have demonstrated impressive efficacy. For example, the STEP 1 trial published in 2021 by John Wilding and colleagues in the New England Journal of Medicine showed that once-weekly semaglutide led to an average body weight reduction of 14.9 percent over 68 weeks, compared with 2.4 percent for placebo.

The current draft notes that GLP-1 usage is rising across healthcare settings, and that adoption rates have surpassed previous levels. National prescribing data confirm this. According to a 2023 report from the IQVIA Institute, GLP-1 prescriptions in the United States increased by more than 300 percent between 2020 and 2022. This growth has been driven by expanded FDA approvals for weight management, increased insurance coverage in certain plans, and growing public awareness through media and social channels. Providers are increasingly offering these medications as first-line options for patients with obesity, especially those who have not responded to lifestyle interventions alone.

The trend builds steadily over time, with no signs of slowing. A 2024 analysis in JAMA Health Forum by Kao-Ping Chua and colleagues estimated that nearly 5 percent of U.S. adults were prescribed a GLP-1 receptor agonist in 2023, up from less than 1 percent in 2019. The numbers represent a fundamental shift in how obesity is treated: as a chronic condition requiring long-term pharmacotherapy rather than acute intervention alone.

Metabolic Surgery Rates in Decline

Metabolic surgery, encompassing procedures such as Roux-en-Y gastric bypass, sleeve gastrectomy, and adjustable gastric banding, has long been considered the gold standard for durable weight loss and resolution of comorbidities like type 2 diabetes. The Swedish Obese Subjects (SOS) study, begun in 1987 and still ongoing, has demonstrated that bariatric surgery can produce sustained weight loss of 20 to 30 percent of initial body weight and reduce overall mortality by 30 percent over 20 years.

However, the current draft indicates that metabolic surgery procedures have decreased, with lower volumes reported by hospitals and scheduling for such interventions slowing down. This decline is consistent in the available data. A 2023 study published in Surgery for Obesity and Related Diseases by Dr. Marina Kurian and colleagues reviewed national bariatric surgery volumes from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP). They found that the number of primary bariatric procedures in the United States dropped by approximately 15 percent from 2021 to 2022, the first significant decline in a decade.

The reduction appears particularly pronounced among patients with lower body mass indexes (BMI) who might have previously qualified for surgery as a last resort. Now, many of those patients are instead prescribed GLP-1 drugs. Additionally, some surgeons have reported an increase in cancellations due to wait times, as patients opt to try medical management before committing to an operation. The overall rates point to reduced demand, and this shift is reshaping hospital resource allocation and surgical training programs.

Trends Moving in Opposite Directions

The draft highlights a clear inverse pattern: as GLP-1 uptake rises, metabolic surgery rates fall. The two curves move in opposite directions, and the relationship holds in the examined timeframe. While correlation does not prove causation, the temporal association is strong.

Several factors explain this connection. First, the efficacy of newer GLP-1 agents has narrowed the weight loss gap between drugs and surgery. Historically, surgery offered 25 to 30 percent total body weight loss, while earlier medications achieved only 5 to 10 percent. But with semaglutide at 15 percent and tirzepatide at over 20 percent in the SURMOUNT-1 trial (published by Dr. Ania Jastreboff and colleagues in 2022), the difference is no longer as dramatic. For many patients, the prospect of an injection every week seems less invasive than an operation that permanently alters gastrointestinal anatomy.

Second, access and cost dynamics play a role. GLP-1 prescriptions can be obtained from primary care providers, whereas bariatric surgery often requires referral to a specialist, preoperative dietary counseling, and insurance preauthorization with strict BMI criteria. The relative ease of starting a medication likely accelerates uptake. Conversely, as demand for GLP-1s grows, some payers have begun to restrict surgical coverage, viewing drugs as a lower-cost alternative in the short term.

Third, patient preferences have evolved. Surveys indicate that many individuals with obesity are hesitant to undergo surgery due to fear of complications, permanent changes, or the stigma of “taking the easy way out.” GLP-1 drugs, while requiring lifelong use, offer a reversible option. This psychological aspect likely contributes to the rising prescription counts and falling surgical volumes.

Market Shifts in Treatment Options

The market for metabolic treatments is undergoing a clear realignment. GLP-1 receptor agonists have captured an increasing share of the obesity treatment market, while surgery options face reduced utilization. The draft notes that these changes shape the competitive field and that providers are adapting based on these dynamics.

Pharmaceutical companies have responded aggressively. Novo Nordisk is expanding its semaglutide manufacturing capacity, and Eli Lilly is investing heavily in tirzepatide. Both are developing oral formulations to compete further. In contrast, hospitals and surgical centers that previously invested heavily in bariatric programs are now adjusting their business models. Some are adding medical weight management clinics to retain patients who might otherwise bypass surgery entirely.

However, it is important to note that metabolic surgery is not disappearing. It remains the most effective intervention for patients with severe obesity (BMI above 40) or for those who have failed multiple medication trials. The decline is relative, not absolute. A 2024 commentary in Obesity Reviews by Dr. Scott Kahan noted that the two approaches may increasingly be used in sequence: patients might start with GLP-1 therapy to lose significant weight and achieve better surgical candidacy, then undergo surgery to sustain long-term results.

The draft concludes that GLP-1 fills a space once held by surgery, but the relationship may be more complementary than purely competitive. The overall picture shows adaptation in care delivery, with clinicians now having a broader toolkit than ever before. The key challenge ahead is ensuring that patients receive appropriate, individualized treatment rather than being steered solely by market forces.

Frequently Asked Questions

Q: How do GLP-1 drugs compare to metabolic surgery for weight loss?

A: Both are effective, but surgery generally produces more dramatic and durable results. Clinical trials show semaglutide leads to around 15 percent weight loss on average, while tirzepatide can exceed 20 percent. Bariatric surgery typically results in 25 to 30 percent weight loss, with long-term maintenance over decades. However, GLP-1 drugs are less invasive, reversible, and increasingly accessible, making them an attractive first option for many patients.

Q: Are GLP-1 drugs a permanent replacement for metabolic surgery?

A: Not for all patients. GLP-1 drugs require continuous use to maintain weight loss, and discontinuation often leads to rebound weight gain. Surgery provides a more durable solution by physically restricting intake and altering gut hormones. Experts suggest that GLP-1 therapy may reduce the need for surgery in milder cases, but for those with severe obesity, surgery remains the gold standard.

Q: What are the main drawbacks of GLP-1 drugs compared to surgery?

A: GLP-1 drugs commonly cause gastrointestinal side effects such as nausea, vomiting, and diarrhea. They require lifelong adherence and can be costly, with monthly prices often exceeding $1,000 without insurance. Additionally, long-term safety data beyond a few years is still accumulating. Surgery, while irreversible, has a one-time cost and established long-term outcomes, though it carries surgical risks and requires permanent lifestyle changes.

Q: Will metabolic surgery eventually become obsolete?

A: Unlikely in the near future. While the number of procedures has declined, surgery remains essential for patients who do not respond to or cannot tolerate GLP-1 therapy, and for those who achieve significant weight loss medically but need surgical support to maintain it. The field is evolving toward a more integrated model where drugs and surgery are used in a stepwise or combined approach, rather than one replacing the other entirely.